Overall Survival and Progression-free Survival among IMDC... | Download Scientific Diagram
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Biomedicines | Free Full-Text | Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
JCM | Free Full-Text | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials - The Lancet Oncology
Frontiers | Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma - Clinical Genitourinary Cancer
![PDF] A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d3b16db9eabd1de88c5804ee9f58ba84a6374e66/5-Figure1-1.png "PDF] A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar")
PDF] A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Semantic Scholar
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | NEJM
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Clinical Trials | VOTRIENT® (pazopanib) tablets
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Full article: Pazopanib for the treatment of soft-tissue sarcoma
![PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/343485ee055845a60e57da69b711a4ea3bb2d505/4-Figure2-1.png "PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar")
PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort - Mustafa Karaağaç, Yasin Sezgin, Melek Karakurt Eryılmaz, Murat Araz, Muhammet Ali
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
